Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Juno Therapeutics Inc.

Division of Celgene Corp.
www.junotherapeutics.com

Latest From Juno Therapeutics Inc.

J.P. Morgan Roundtable: Making Deals And Managing Alliances As Technologies Advance

Part 2: Scrip spoke with companies working on cell and gene therapies and novel neurology approaches during the J.P. Morgan Healthcare Conference about the dos and don'ts of deal-making as they advance innovative programs into the clinic and beyond.

Deals StartUps and SMEs

Celgene Gives Reassurances That Key Products And Programs Remain On Track

Celgene's quarterly earnings call was all about reassuring investors that its products and pipeline will deliver the full value of the company's acquisition by Bristol-Myers after the deal closes in the third quarter.

Sales & Earnings Research and Development Strategies

Finance Watch: Recent Offerings Show Some Companies Were Ready For The Government Shutdown

Public Company Edition: The usual mid-January surge in public offerings hasn't happened this year, since the SEC can't process new filings, but Alnylam, Acceleron and others apparently were prepared for a lengthy shutdown. Also, ARM reports cell and gene therapy financing data.

Financing Business Strategies

2018’s Top Biopharma Deal-makers

Even though 2018 did not feature the big influx of biopharma M&A that was expected, there were still encouraging signs that major advancements and breakthroughs in the biotech industry attract buy-outs. Cancer-focused companies and oncology assets again drove volume in alliances and financing transactions.

Deals Market Intelligence
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register